

1 **The combination of aggressive hydration and rectal non-steroidal anti-**
2 **inflammatory drugs is not superior to rectal non-steroidal anti-inflammatory**
3 **drugs alone in the prevention of pancreatitis after endoscopic retrograde**
4 **cholangiopancreatography: a systematic review and meta-analysis**

5
6 **Xiang Cheng^{1,2†}, Feixiang Yang^{2†}, Xingxin Yang³, Ning Zhang², Xiaoming Li^{3*}, Bo Chen^{1*}**

7
8 ¹ Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Hefei
9 230022, China.

10 ² First School of Clinical Medicine, Anhui Medical University, Hefei 230032, China.

11 ³ Department of Medical Psychology, School of Mental Health and Psychological Sciences, Anhui
12 Medical University, Hefei 230032, China.

13
14 † These authors contributed equally to this work.

15
16 *** Correspondence:**

17 Bo Chen

18 chenbo@ahmu.edu.cn

19 Xiaoming Li

20 psyxiaoming@126.com

21 **Abstract**

22 **Background:** endoscopic retrograde cholangiopancreatography (ERCP) can lead to many high-risk
23 complications, of which acute pancreatitis is the most prevalent and serious one. Whether patients who
24 receive prophylactic rectal non-steroidal anti-inflammatory drugs (NSAIDs) need to be combined with
25 aggressive hydration remains controversial.

26 **Aim:** The study was performed to determine whether there is collaborative facilitation between rectal
27 NSAIDs and aggressive hydration in preventing post-ERCP pancreatitis (PEP).

28 **Methods:** We searched all eligible studies on the preventive effects of active rehydration and NSAIDs
29 on PEP from multiple databases including ClinicalTrials, PubMed, CQVIP, Embase, Web of Science,
30 CNKI, Cochrane Library, and Wanfang Data. We performed a meta-analysis of the data related to the
31 incidence of PEP as well as the serious cases including the incidence of severe PEP and mortality.

32 **Results:** This meta-analysis included three published studies of randomized controlled trials with 1110
33 patients. Our results showed that additional aggressive hydration was not significantly effective for the
34 prevention of PEP in patients who were already receiving rectal NSAIDs (odds ratio [OR], 0.43; 95%
35 confidence interval [CI], 0.12-1.57; P=0.20). With regard to the prevention of serious cases, compared
36 with rectal NSAIDs alone, aggressive fluid hydration combined with rectal NSAIDs did not reduce the
37 morbidity of severe PEP (OR, 0.32; 95% CI, 0.10-1.08; P=0.07), nor did it reduce overall mortality (OR,
38 0.81; 95% CI, 0.28-2.36; P=0.70).

39 **Conclusion:** Aggressive perioperative hydration combined with rectal NSAIDs was not superior to rectal
40 NSAIDs along in the prevention of PEP.

41
42 **Keywords:** Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic
43 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Retrograde; Fluid Therapy; Meta-Analysis; Systematic Review

44 **Introduction**

45 Endoscopic retrograde cholangiopancreatography (ERCP) is conducted to evaluate the pathological
46 changes in bile duct, pancreatic duct, and hepatopancreatic ampullae, such as stones, tumors, and
47 inflammation [1]. The improvement of endoscopic technology advances the application of ERCP in the
48 diagnosis and management of pancreatic and biliary tract diseases, making ERCP a major diagnostic and
49 therapeutic intervention for biliopancreatic lesions [2]. Post-ERCP pancreatitis (PEP) is the most
50 prevalent and serious ERCP-associated complication, with an incidence that ranges between 3% and 5%
51 in low-risk patients and as high as 15% in high-risk patients [1-4]. ERCP induces pancreatic injury and
52 inflammation in two main mechanisms: mechanical damage from instrument handling and hydrostatic
53 compression damage from contrast media [5, 6]. There are many ERCP procedures involving prolonged
54 instrument operation of the pancreatic duct, such as long-term or repeated pancreatic intubation, which
55 can cause direct injury to the pancreatic duct or ampulla. In addition, some procedures operated by an
56 electric knife can result in mechanical and thermal injury, subsequently lead to secondary trypsin injury
57 after reactive edema and obstruction of the pancreatic duct [5]. The pancreatic injury induced by contrast
58 mainly includes hydrostatic compression damaged by overuse of contrast or chemical or allergic damage
59 induced by contrast [5-7]. Although George *et al.* found that no remarkable difference existed in the
60 incidence of PEP between high and low-osmolality contrast, the role of contrast in pancreatic damage
61 remains controversial [8]. Other underlying mechanisms include zymogen activation, genetic defects,
62 and flora disorder, however, these do not affect as large as mechanical damage or contrast damage to
63 pancreatic injury [9].

64 PEP is defined as the elevation of serum amylase level more than three times the upper limit of
65 normal within 24 hours, accompanied by typical clinical symptoms of pancreatitis, such as persistent
66 pancreatitis-like abdominal pain [10]. There are many academic discussions on effective strategies to
67 prevent PEP, among them, pancreatic duct stenting and perioperative rectal nonsteroidal anti-
68 inflammatory drugs (NSAIDs) are widely accepted [11-13]. Additionally, aggressive hydration has been
69 also recommended by clinical researchers due to its promising preventive effect [14, 15]. The mechanism
70 of NSAIDs in preventing acute pancreatitis is related to their potent inhibitory effects on cyclooxygenase,
71 phospholipase A2, and interaction between neutrophils and endothelial cells, which activate
72 inflammatory cascade and lead to pancreatitis [16]. NSAIDs are an attractive option to prevent PEP
73 because of their affordability and easy patient management [17]. There is evidence that aggressive
74 perioperative hydration presents satisfactory efficacy in prevention of PEP [18-23]. Hydration improves
75 blood perfusion and stabilizes the pancreatic microcirculation by attenuating tissue acidification,
76 improving the prognosis of patients [24-27]. The mechanism of hydration is to protect the pancreatic
77 microcirculation and NSAIDs are aimed at suppressing the inflammatory response, however, whether
78 hydration and rectal NSAIDs exhibit synergistic effects remains unclear [28-31]. The discussion on this
79 issue is still controversial [17, 32]. Therefore, we comprehensively reassess the efficacy of aggressive
80 hydration with rectal NSAIDs in comparison with rectal NSAIDs alone, providing evidence-based
81 support for the prevention of PEP.

82 **Methods**

83 **Search strategy**

84 The study comprehensively searched ClinicalTrials, PubMed, CQVIP, Embase, Web of Science,

85 CNKI, Cochrane Library, and Wanfang Data, and searched for all relevant articles published before
86 September 2021. After several attempts, we chose to sacrifice a little precision to ensure the
87 comprehensiveness of the search, while comparing several meta-analyses related to the content of this
88 study, and finally determined the search formula for this study. The search formula applied in PubMed is
89 as follows: (post-ercp [All Fields] AND ("pancreatitis" [MeSH Terms] OR "pancreatitis" [All Fields])
90 AND ("prevention and control" [Subheading] OR ("prevention" [All Fields] AND "control" [All Fields])
91 OR "prevention and control" [All Fields] OR "prevention" [All Fields])) AND (randomized controlled
92 trial [Publication Type] OR randomized [Title/Abstract] OR placebo [Title/Abstract]).

93 **Inclusion and exclusion criteria**

94 We included all randomized controlled trials that contained a comparison of the efficacy of rectal
95 NSAIDs and rectal NSAIDs in combination with active fluid hydration for PEP prevention. Our inclusion
96 criteria included the following: a) RCTs that directly compared rectal NSAIDs combined with aggressive
97 hydration and rectal NSAIDs alone; b) our primary outcome was the rate of PEP and secondary outcomes
98 were the rate of severe and fatal cases of PEP (PEP was defined as serum amylase levels three times
99 higher than the upper limit of normal within 24 hours after ERCP and persistent pancreatitis-like
100 abdominal pain was observed). We excluded the following: a) RCTs in relation to combination of rectal
101 NSAIDs and pancreatic duct stents or RCTs that did not contain aggressive hydration; b) studies that did
102 not report complete experimental data or whose full text were not available; c) not RCTs.

103 **Data extraction and management**

104 We determined a data extraction table after several tests in advance. Two independent reviewers
105 extracted data from the included literature using the unified form. The main information extracted from
106 the data extraction form included: lead author, year of publication, patient demographics (ie, country,
107 mean age, sex), sample size, intervention measure (ie, type of NSAIDs, NSAIDs dose, type of infusion
108 fluid, duration and volume of infusion), prevalence of PEP, mortality, and incidence of adverse effects
109 for each study. We also extracted relevant patient metrics and complication data that may be useful for
110 each experiment. In case of disagreement between two reviewers, the third reviewer negotiated and
111 resolved it. All reviewers agreed at the final results.

112 **Risk of bias assessment**

113 We evaluated the risk of bias in the relevant literature according to the seven aspects included in the
114 Cochrane Handbook for Systematic Reviews of Interventions, including publication bias, time lag bias,
115 multiple publication bias, publication position bias, citation bias, language bias, and outcome reporting
116 bias. We also assessed the quality of the evidence based on GRADE ratings, which evaluate evidence
117 quality depending on study limitations, inconsistency of results, indirectness of evidence, imprecision of
118 results, and reporting bias. We classified the quality of evidence into four levels (high, moderate, low, or
119 very low).

120 **Statistical analysis**

121 Statistical analysis was performed by RevMan software (version 5.4). Data were collected with
122 dichotomous variables, and odds ratios (OR) and 95% confidence intervals (CI) were calculated.
123 Statistical heterogeneity between studies was measured by I^2 , and significant heterogeneity was indicated
124 when $I^2 > 50\%$. If the heterogeneity is not significant, a model or a random-effects model is generally
125 employed. Conversely, only the fixed-effects model is used while the heterogeneity is significant. We
126 performed statistical analysis of studies data using the random-effects model in this meta-analysis.

127 Statistical significance was considered when the p-value < 0.05. Although the number of included
128 literatures was small, a sensitivity analysis was still performed. Sensitivity analysis showed that our
129 results were not affected by the heterogeneity of different literatures.

130 **Results**

131 **Search results**

132 1355 relevant articles were found from ClinicalTrials, PubMed, CQVIP, Embase, Web of Science,
133 CNKI, Cochrane Library, and Wanfang Data. We showed the complete retrieval process and screening
134 details in **Figure 1**. After multiple screening, literatures not included in the inclusion criteria or with
135 missing data were excluded. Finally, three RCTs with 1110 patients were included in this study and
136 related results were presented in **Figures 1-5** and **Table 2**. The PRISMA statement was followed in the
137 review process of our systematic review [33].

138 **Characteristics of trials**

139 We included 3 published studies of RCTs with 1110 patients. Of these three RCTs, two studies were
140 in the United States [34, 35] and one study was in Iran [17]. One was published in 2021, one in 2017,
141 and one in 2016, all relatively novel studies within five years of each other and of good reference value.
142 The three included studies were full-text papers. With respect to hydration reagent, in one study, the
143 experimental group was injected with normal saline, while the control group did not [17]; and in the other
144 two studies [34, 35], Lactate Ringer solution was used in experimental group, while normal saline was
145 used in control group. For NSAIDs, two trials were administered indomethacin [17, 34], and one trial
146 was administered indomethacin or diclofenac randomly [35]. All trials were administered rectally at a
147 dose of 100mg. More details such as patient information, interventions were presented in **Table 1**.

148 **Risk of bias in included studies**

149 Among three RCTs, one study [34] was single-blinded study. Two studies [17, 35] were double
150 blinded studies. One study [35] did not provide enough information about incomplete outcome data
151 (attrition bias), while another two studies [17, 34] provided complete data in incomplete outcome data.
152 Funnel plots cannot assess true asymmetry when the sample size is less than 5 studies, so funnel plots
153 were not used to assess publication bias [36]. The assessment of publication bias of the included studies
154 was shown in **Figure 2**.

155 **Effects of interventions**

156 **Incidence of PEP**

157 Three studies [17, 34, 35] have reported this result involving 1110 patients. Since significant
158 heterogeneity was found with $I^2 > 50\%$, we used the random-effects model. The results showed that there
159 was no remarkable difference between patients receiving rectal NSAIDs alone and those receiving
160 aggressive hydration in combination with NSAIDs in terms of incidence of PEP (OR, 0.43; 95% CI,
161 0.12-1.57; P=0.20). The forest plot was shown in **Figure 3**.

162 **incidence of severe PEP**

163 Two studies [34, 35] have reported this result including 909 patients. Although I^2 is less than 50%, the
164 random-effects model is still applicable. The results showed that there was no remarkable difference in
165 the incidence of severe PEP between rectal NSAIDs alone and aggressive hydration with rectal NSAIDs

166 (OR, 0.32; 95% CI, 0.10-1.08; P=0.07). The forest plots are shown in **Figure 4**.

167 **Incidence of fatal PEP**

168 Two studies [34, 35] have reported this result with 909 patients. We used the random-effects model
169 with I²<50%. The results revealed that there was also no remarkable difference in the incidence of fatal
170 cases between rectal NSAIDs alone and aggressive hydration combined with rectal NSAIDs (OR, 0.81;
171 95% CI, 0.28–2.36; P=0.70). The forest plots are shown in **Figure 5**.

172 **Summary of findings and quality of evidence**

173 We evaluated the quality of evidence for the role of aggressive hydration in preventing PEP based
174 on GRADE ratings. Evidence level for evaluating PEP prevention in the group receiving aggressive
175 hydration versus the standard group was moderate. Evidence level for evaluating severe PEP prevention
176 in the group receiving aggressive hydration versus the standard group was very low. Evidence level for
177 evaluating preventive effect on fatal PEP in the group receiving aggressive hydration versus the standard
178 group was very low. The relevant study results and GRADE recommendations are in **Table 3**.

179 **Discussion**

180 We did a meta-analysis reviewing three RCTs with 1110 patients. The results showed that the
181 combination of prophylactic rectal NSAIDs and perioperative hydration in experimental group did not
182 decrease the incidence of PEP compared with rectal NSAIDs alone in standard group. Meanwhile, the
183 combination therapy had no higher effect in preventing serious cases in comparison to NSAIDs
184 individually, with not significantly different incidence of severe PEP and fatal cases.

185 As an essential diagnostic and therapeutic tools of pancreaticobiliary diseases, ERCP is widely
186 performed but also presents some complications. Among of them, exhibiting a high incidence and
187 severity, PEP is receiving widespread attention. Although the identifying and managing the risk factors
188 associated with ERCP can minimize the associated complications, the prevalence of PEP continues to be
189 high. The last decade has witnessed a tremendous advance in prevention strategies for PEP, application
190 of NSAIDs and placement of pancreatic duct stents have been broadly recognized in clinical practice for
191 avoiding this serious complication. In particular, rectal NSAIDs, which have dropped the development
192 of PEP significantly in 60% of cases. Moreover, a network meta-analysis including 29 studies showed
193 that rectal NSAIDs alone presented superior results in preventing PEP compared with pancreatic duct
194 stents alone (OR, 0.48; 95% CI, 0.26-0.87) [17]. Despite the use rectal NSAIDs, a high incidence of PEP
195 persists due to some contraindicated populations or intolerance to NSAIDs. Recently, perioperative
196 hydration has been recognized by several evidence-based guidance sourced form meta-analysis-level
197 evidence, often with astonishing benefits in terms of decreased risk and improved prognosis, offering a
198 new nonpharmacologic measure to reduce the morbidity and severity of PEP [18, 37]. A published meta-
199 analysis including 10 RCTs with 2200 patients showed that aggressive intravenous infusion with Lactate
200 Ringer solution was superior to standard intravenous infusion in protecting high-risk groups from PEP
201 (OR, 0.40; 95% CI, 0.26-0.63; P < .0001) [34]. Furthermore, the positive role of aggressive hydration in
202 decreasing the risk of developing PEP versus standard hydration was directly demonstrated in two
203 randomized controlled trials respectively conducted by Buxbaum *et al.* (0 [0%] of 39 patients vs 4 [17%]
204 of 23 patients; 95% CI of difference 5.8, 35.9%; p=0.016) and Choi *et al.* (11 [4.3%] of 255 vs 25 [9.8%]
205 of 255 patients; relative risk [RR], 0.41; 95% CI, 0.20-0.86; P = .016) [35, 38]. These studies led to
206 international treatment guidelines recommending preoperative aggressive hydration to lower the risk of

207 PEP [39, 40]. It has been suggested that combined aggressive hydration on the basis of rectal NSAIDs
208 might further diminish the occurrence of PEP. However, whether there is a collaborative facilitation
209 between rectal NSAIDs and aggressive hydration remains obscure.

210 Herein, we did a meta-analysis to assess the efficacy of additional aggressive hydration on patients
211 receiving rectal NSAIDs already. Our meta-analysis showed that patients receiving aggressive fluid
212 hydration (with Lactate Ringer solution or normal saline) plus rectal NSAIDs (100mg indomethacin or
213 diclofenac) before or after ERCP procedure exhibited similar outcomes as patients who received rectal
214 NSAIDs alone (or combined with restricted hydration), that is, the incidence of PEP was not significantly
215 different (OR, 0.43; 95% CI, 0.12-1.57; P=0.20). A previous network meta-analysis presented analogous
216 results to our study that the combination of aggressive fluid hydration with Lactate Ringer solution and
217 rectal diclofenac 100 mg had no significant difference in preventing PEP over rectal diclofenac 100 mg
218 alone (OR, 0.49; 95% CI, 0.26–0.94; low confidence). However, with regard to indomethacin, this meta-
219 analysis concluded that the efficacy of the combination of standard hydration with normal saline and
220 rectal indomethacin 100 mg surpassed rectal indomethacin 100 mg alone in preventing PEP (OR, 0.04;
221 95% CI, 0.00–0.66; moderate confidence) [14]. Several meta-analysis-based evidences had shown that
222 the efficacy of indomethacin and diclofenac was similar [16, 39]. There was a high probability of false-
223 positive results, on account of small sample sizes that included 1 RCT associated with rectal
224 indomethacin combined standard hydration trials in this network meta-analysis. On the other hand, our
225 results showed that no remarkable difference existed between patients receiving rectal NSAIDs alone
226 and those receiving aggressive fluid hydration combined with rectal NSAIDs in incidence of severe PEP
227 (OR, 0.32; 95% CI, 0.10-1.08; P=0.07) and fatal cases (OR, 0.81; 95% CI, 0.28–2.36; P=0.70). Therefore,
228 the intravenous fluid hydration with 8-10 hours may be laborious and time-consuming for patients
229 received rectal NSAIDs already. However, intravenous fluid infusion is still the optimal choice for
230 patients with contraindications to NSAIDs due to its inexpensive and efficient nature.

231 Some shortcomings and limitations of our meta-analysis included the following: First, the number
232 of includable literatures was not sufficient, and only three RCTs met the requirements. Secondly, sample
233 size of some included RCTs was excessively limited, which could not exclude the possibility of false-
234 positive or false-negative results. Third, the different intervention measures in respective RCT studies
235 may increase the heterogeneity of our results. For instance, one RCT study [17] included in our meta-
236 analysis compared the preventive effect of rectal indomethacin alone to the combination of intravenous
237 normal saline and rectal indomethacin; And another RCT study [35] compared the efficacy of rectal
238 indomethacin with intravenous Lactate Ringer solution to rectal indomethacin with intravenous normal
239 saline in preventing PEP. However, the sensitivity analysis had shown that our final results were not
240 affected by these different interventions.

241 In conclusion, aggressive perioperative hydration combined with rectal NSAID presented a modest
242 effect in reducing the rate of PEP for patients received rectal NSAIDs already. Additionally, the
243 combination therapy of aggressive hydration and rectal NSAIDs showed poor efficacy in preventing
244 severe and fatal PEP. To some extent, aggressive hydration may be not necessary for patients who have
245 received rectal NSAIDs.

246 **Statements and Declarations**

247 There is no conflict of interest associated with this article.

248 Funding

249 This work was funded by Quality Engineering Project of Anhui Province (No.2020jyxm0898 ;
250 No.2020jyxm0910, No.2019kfk334), Clinical research project of Anhui Medical University
251 (No.2020xkj176) and Soft health science research of Anhui province-Major project (No.2020WR01003).

252 References

- 253 1. Baiu I, Visser B: **Endoscopic Retrograde Cholangiopancreatography**. *Jama* 2018, **320**:2050.
- 254 2. Kochar B, Akshintala VS, Afghani E, Elmunzer BJ, Kim KJ, Lennon AM, Khashab MA, Kalloo AN,
255 Singh VK: **Incidence, severity, and mortality of post-ERCP pancreatitis: a systematic review by
256 using randomized, controlled trials**. *Gastrointest Endosc* 2015, **81**:143-149.e149.
- 257 3. Chen JJ, Wang XM, Liu XQ, Li W, Dong M, Suo ZW, Ding P, Li Y: **Risk factors for post-ERCP
258 pancreatitis: a systematic review of clinical trials with a large sample size in the past 10 years**.
259 *Eur J Med Res* 2014, **19**:26.
- 260 4. Ding X, Zhang F, Wang Y: **Risk factors for post-ERCP pancreatitis: A systematic review and
261 meta-analysis**. *Surgeon* 2015, **13**:218-229.
- 262 5. Obeidat AE, Mahfouz R, Monti G, Kozai L, Darweesh M, Mansour MM, Alqam A, Hernandez D:
263 **Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: What We Already
264 Know**. *Cureus* 2022, **14**:e21773.
- 265 6. Wong LL, Tsai HH: **Prevention of post-ERCP pancreatitis**. *World J Gastrointest Pathophysiol*
266 2014, **5**:1-10.
- 267 7. Freeman ML, Guda NM: **Prevention of post-ERCP pancreatitis: a comprehensive review**.
268 *Gastrointest Endosc* 2004, **59**:845-864.
- 269 8. George S, Kulkarni AA, Stevens G, Forsmark CE, Draganov P: **Role of osmolality of contrast
270 media in the development of post-ERCP pancreatitis: a metanalysis**. *Dig Dis Sci* 2004, **49**:503-
271 508.
- 272 9. Tryliskyy Y, Bryce GJ: **Post-ERCP pancreatitis: Pathophysiology, early identification and risk
273 stratification**. *Adv Clin Exp Med* 2018, **27**:149-154.
- 274 10. Cotton PB, Lehman G, Vennes J, Geenen JE, Russell RC, Meyers WC, Liguory C, Nickl N:
275 **Endoscopic sphincterotomy complications and their management: an attempt at consensus**.
276 *Gastrointest Endosc* 1991, **37**:383-393.
- 277 11. Elmunzer BJ, Scheiman JM, Lehman GA, Chak A, Mosler P, Higgins PD, Hayward RA,
278 Romagnuolo J, Elta GH, Sherman S, et al: **A randomized trial of rectal indomethacin to prevent
279 post-ERCP pancreatitis**. *N Engl J Med* 2012, **366**:1414-1422.
- 280 12. Serrano JPR, de Moura DTH, Bernardo WM, Ribeiro IB, Franzini TP, de Moura ETH, Brunaldi VO,
281 Salesse MT, Sakai P, De Moura EGH: **Nonsteroidal anti-inflammatory drugs versus placebo for
282 post-endoscopic retrograde cholangiopancreatography pancreatitis: a systematic review and
283 meta-analysis**. *Endosc Int Open* 2019, **7**:E477-e486.
- 284 13. Sugimoto M, Takagi T, Suzuki R, Konno N, Asama H, Sato Y, Irie H, Watanabe K, Nakamura J,
285 Kikuchi H: **Pancreatic stents to prevent post-endoscopic retrograde
286 cholangiopancreatography pancreatitis: a meta-analysis**. *World J Metaanal* 2019, **7**:249-258.
- 287 14. Akshintala VS, Sperna Weiland CJ, Bhullar FA, Kamal A, Kanthasamy K, Kuo A, Tomasetti C,
288 Gurakar M, Drenth JPH, Yadav D, et al: **Non-steroidal anti-inflammatory drugs, intravenous
289 fluids, pancreatic stents, or their combinations for the prevention of post-endoscopic**

- 290 **retrograde cholangiopancreatography pancreatitis: a systematic review and network meta-**
291 **analysis.** *Lancet Gastroenterol Hepatol* 2021, **6**:733-742.
- 292 15. Buxbaum J: **Aggressive hydration and post-ERCP pancreatitis.** *Lancet Gastroenterol Hepatol*
293 2021, **6**:686.
- 294 16. Patai Á, Solymosi N, Mohácsi L, Patai Á V: **Indomethacin and diclofenac in the prevention of**
295 **post-ERCP pancreatitis: a systematic review and meta-analysis of prospective controlled**
296 **trials.** *Gastrointest Endosc* 2017, **85**:1144-1156.e1141.
- 297 17. Hosseini M, Shalchiantabrizi P, Yektaroudy K, Dadgarmoghaddam M, Salari M: **Prophylactic**
298 **Effect of Rectal Indomethacin Administration, with and without Intravenous Hydration, on**
299 **Development of Endoscopic Retrograde Cholangiopancreatography Pancreatitis Episodes: A**
300 **Randomized Clinical Trial.** *Arch Iran Med* 2016, **19**:538-543.
- 301 18. Buxbaum J, Yan A, Yeh K, Lane C, Nguyen N, Laine L: **Aggressive hydration with lactated**
302 **Ringer's solution reduces pancreatitis after endoscopic retrograde**
303 **cholangiopancreatography.** *Clin Gastroenterol Hepatol* 2014, **12**:303-307.e301.
- 304 19. DiMagno MJ, Wamsteker EJ, Maratt J, Rivera MA, Spaete JP, Ballard DD, Elmunzer J, Saini SD:
305 **Do larger periprocedural fluid volumes reduce the severity of post-endoscopic retrograde**
306 **cholangiopancreatography pancreatitis?** *Pancreas* 2014, **43**:642-647.
- 307 20. Sagi SV, Schmidt S, Fogel E, Lehman GA, McHenry L, Sherman S, Watkins J, Coté GA: **Association**
308 **of greater intravenous volume infusion with shorter hospitalization for patients with post-**
309 **ERCP pancreatitis.** *J Gastroenterol Hepatol* 2014, **29**:1316-1320.
- 310 21. Shaygan-Nejad A, Masjedizadeh AR, Ghavidel A, Ghojazadeh M, Khoshbaten M: **Aggressive**
311 **hydration with Lactated Ringer's solution as the prophylactic intervention for**
312 **postendoscopic retrograde cholangiopancreatography pancreatitis: A randomized controlled**
313 **double-blind clinical trial.** *J Res Med Sci* 2015, **20**:838-843.
- 314 22. Grunwald D, Wadhwa V, Sawhney MS: **Hemodynamic Variation and Intravenous Fluids**
315 **Administered During ERCP and the Association With Post-ERCP Pancreatitis.** *Pancreas* 2016,
316 **45**:293-297.
- 317 23. Zhang ZF, Duan ZJ, Wang LX, Zhao G, Deng WG: **Aggressive Hydration With Lactated Ringer**
318 **Solution in Prevention of Postendoscopic Retrograde Cholangiopancreatography Pancreatitis:**
319 **A Meta-analysis of Randomized Controlled Trials.** *J Clin Gastroenterol* 2017, **51**:e17-e26.
- 320 24. Rinderknecht H: **Activation of pancreatic zymogens. Normal activation, premature**
321 **intrapancreatic activation, protective mechanisms against inappropriate activation.** *Dig Dis*
322 *Sci* 1986, **31**:314-321.
- 323 25. Kusterer K, Enghofer M, Zendler S, Blöchle C, Usadel KH: **Microcirculatory changes in sodium**
324 **taurocholate-induced pancreatitis in rats.** *Am J Physiol* 1991, **260**:G346-351.
- 325 26. Strate T, Mann O, Kleinhans H, Rusani S, Schneider C, Yekebas E, Freitag M, Standl T, Bloechle
326 C, Izbicki JR: **Microcirculatory function and tissue damage is improved after therapeutic**
327 **injection of bovine hemoglobin in severe acute rodent pancreatitis.** *Pancreas* 2005, **30**:254-
328 259.
- 329 27. Wu BU, Hwang JQ, Gardner TH, Repas K, Delee R, Yu S, Smith B, Banks PA, Conwell DL: **Lactated**
330 **Ringer's solution reduces systemic inflammation compared with saline in patients with acute**
331 **pancreatitis.** *Clin Gastroenterol Hepatol* 2011, **9**:710-717.e711.
- 332 28. Mäkelä A, Kuusi T, Schröder T: **Inhibition of serum phospholipase-A2 in acute pancreatitis by**
333 **pharmacological agents in vitro.** *Scand J Clin Lab Invest* 1997, **57**:401-407.

- 334 29. Cuthbertson CM, Christophi C: **Disturbances of the microcirculation in acute pancreatitis.** *Br*
335 *J Surg* 2006, **93**:518-530.
- 336 30. Coté GA, Sagi SV, Schmidt SE, Lehman GA, McHenry L, Fogel E, Watkins J, Sherman S: **Early**
337 **measures of hemoconcentration and inflammation are predictive of prolonged**
338 **hospitalization from post- endoscopic retrograde cholangiopancreatography pancreatitis.**
339 *Pancreas* 2013, **42**:850-854.
- 340 31. Gross V, Leser HG, Heinisch A, Schölmerich J: **Inflammatory mediators and cytokines--new**
341 **aspects of the pathophysiology and assessment of severity of acute pancreatitis?**
342 *Hepatogastroenterology* 1993, **40**:522-530.
- 343 32. Hajalikhani M, Emami MH, Khodadoostan M, Shavakhi A, Rezaei M, Soluki R: **Combination of**
344 **diclofenac and aggressive hydration for the prevention of post-ERCP pancreatitis.**
345 *Gastroenterology and hepatology from bed to bench* 2018, **11**:319-324.
- 346 33. Moher D, Liberati A, Tetzlaff J, Altman DG: **Preferred Reporting Items for Systematic Reviews**
347 **and Meta-Analyses: The PRISMA Statement.** *Plos Medicine* 2009, **6**.
- 348 34. Mok SRS, Ho HC, Shah P, Patel M, Gaughan JP, Elfant AB: **Lactated Ringer's solution in**
349 **combination with rectal indomethacin for prevention of post-ERCP pancreatitis and**
350 **readmission: a prospective randomized, double-blinded, placebo-controlled trial.**
351 *Gastrointestinal Endoscopy* 2017, **85**:1005-1013.
- 352 35. Serna Weiland CJ, Smeets XJNM, Kievit W, Verdonk RC, Poen AC, Bhalla A, Venneman NG,
353 Witteman BJM, da Costa DW, van Eijck BC, et al: **Aggressive fluid hydration plus non-steroidal**
354 **anti-inflammatory drugs versus non-steroidal anti-inflammatory drugs alone for post-**
355 **endoscopic retrograde cholangiopancreatography pancreatitis (FLUYT): a multicentre, open-**
356 **label, randomised, controlled trial.** *The Lancet Gastroenterology & Hepatology* 2021, **6**:350-
357 358.
- 358 36. Al-Omran M, Albalawi ZH, Tashkandi MF, Al-Ansary LA: **Enteral versus parenteral nutrition for**
359 **acute pancreatitis.** *Cochrane Database Syst Rev* 2010, **2010**:Cd002837.
- 360 37. Smeets XJ, da Costa DW, Besselink MG, Bruno MJ, Fockens P, Mulder CJ, van der Hulst RW,
361 Vleggaar FP, Timmer R, Drenth JP, van Geenen EJ: **Systematic review: periprocedural hydration**
362 **in the prevention of post-ERCP pancreatitis.** *Aliment Pharmacol Ther* 2016, **44**:541-553.
- 363 38. Choi JH, Kim HJ, Lee BU, Kim TH, Song IH: **Vigorous Periprocedural Hydration With Lactated**
364 **Ringer's Solution Reduces the Risk of Pancreatitis After Retrograde**
365 **Cholangiopancreatography in Hospitalized Patients.** *Clin Gastroenterol Hepatol* 2017, **15**:86-
366 92.e81.
- 367 39. Chandrasekhara V, Khashab MA, Muthusamy VR, Acosta RD, Agrawal D, Bruining DH, Eloubeidi
368 MA, Fanelli RD, Faulx AL, Gurudu SR, et al: **Adverse events associated with ERCP.** *Gastrointest*
369 *Endosc* 2017, **85**:32-47.
- 370 40. Dumonceau JM, Kapral C, Aabakken L, Papanikolaou IS, Tringali A, Vanbiervliet G, Beyna T,
371 Dinis-Ribeiro M, Hritz I, Mariani A, et al: **ERCP-related adverse events: European Society of**
372 **Gastrointestinal Endoscopy (ESGE) Guideline.** *Endoscopy* 2020, **52**:127-149.

373
374
375
376
377

378 **Table 1** Characteristics of included studies

Study name	Weiland <i>et al.</i>	Mok <i>et al.</i>	Hosseini <i>et al.</i>
Location	USA	USA	Iran
Year	2021	2017	2016
Patient Age, years	≤40 years old, 81 (AH)/67(SH) >40 years old, 307(AH)/358(SH)	Mean Age 63(AH)/62(SH)	Mean ± SD 47.91 ± 11.06(AH)/ 51.20 ± 12.12 (SH)
Sex	Female,232(AH)/250(SH) Male,156(AH)/175(SH)	Female,23(AH)/33(SH) Male,25(AH)/15(SH)	Female,62(AH)/40(SH) Male,39(AH)/60(SH)
Previous pancreatitis	13(AH)/13(SH)	0(AH)/1(SH)	-
Pancreatic duct stent placement	58(AH)/73(SH)	10(AH)/12(SH)	-
Difficult cannulation	113(AH)/123(SH)	6(AH)/8(SH)	-
Trainee involvement	33(AH)/34(SH)	48(AH)/48(SH)	-
Study design	RCT n=813(388AH/425SH)	RCT n=96(48AH/48SH)	RCT n=201(101AH/100SH)
Intervention (AH/SH)	AH: Receive rectal NSAIDs 100mg within 30 min before or after ERCP procedure and 20 mL/kg of Lactate Ringer solution intravenously within 60 minutes as the beginning of the procedure, followed by 3 mL/kg every hour for 8 hours. SH: Receive rectal NSAID 100 mg alone and restrict intravenous infusion of normal saline.	AH: Received preoperative rectal injection of indomethacin 100 mg and preoperative intravenous 1000 ml of Lactate Ringer solution. SH: Received intraoperative intravenous normal saline and preoperative rectal injection of indomethacin 100 mg.	AH: rectal indomethacin and intravenous normal saline. SH: 100 mg of Indomethacin rectally two hours before the ERCP procedure.

379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396

397 **Table 2** Assessment of quality of evidence.

Outcomes	Illustrative comparative risks*(95%CI)		Relative effect (95% CI)	No of Participants(studies)	Quality of the evidence (GRADE)
	Assumed risk NSAIDs alone	Corresponding risk Fluid hydration plus NSAIDs			
PEP	Study population		OR 0.43 (0.12 to 1.57)	1110(3 studies)	⊕ ⊕ ⊕ ⊖ moderate
	98 per 100	45 per 1000 (13 to 145)			
	Moderate				
	110 per 1000	50 per 1000 (15 to 163)			
Severe PEP	Study population		OR 0.32 (0.10 to 1.08)	909 (2studies)	⊕ ⊖ ⊖ ⊖ very low
	23 per 1000	8 per 1000 (2 to 25)			
	Moderate				
	22 per 1000	7 per 1000 (2 to 24)			
Death	Study population		OR 0.81 (0.28 to 2.36)	909 (2studies)	⊕ ⊖ ⊖ ⊖ very low
	17 per 1000	14 per 1000 (5 to 39)			
	Moderate				
	28 per 1000	23 per 1000 (8 to 64)			

398 CI = Confidence interval, OR = Odds ratio, PEP = post -ERCP pancreatitis.

399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420

421 **Table 3** Statistical results of included studies

Groups	No. of Studies (References)	AH/SH	Relative risk (95%CI)	P
Pseudocyst	1(27)	1(48)/0(48)	-	1.00
Exocrine insufficiency	1(28)	0(388)/2(425)	0.40 (0.02–7.69)	0.25
Endocrine insufficiency	1(28)	4(388)/3(425)	1.70 (0.44–6.66)	0.49
Duration of hospital stay, nights	1(28)	1(388)/1(425)	-	0.77
ERCP-related complications	1(28)	16(388)/21(425)	0.90 (0.62–1.31)	0.62
Cholangitis	1(28)	2(388)/6(425)	-	0.44
Bleeding	2(27,28)	10(436)/12(473)	-	0.53
Perforation	1(28)	5(388)/4(425)	-	0.49
Hydration-related complications	1(28)	8(388)/9(425)	0.99 (0.59–1.64)	1.00
Pulmonary oedema	2(27,28)	3(436)/5(473)	-	0.80
Peripheral oedema	1(28)	6(388)/3(425)	-	0.22
Cardiac insufficiency	1(28)	0(388)/3(425)	-	0.25
Hypernatraemia	1(28)	1(388)/1(425)	-	1.00
ICU admission after ERCP	1(28)	2(388)/6(425)	0.37 (0.07–1.80)	0.22
Mortality during 180-day follow-up	1(28)	11(388)/12(425)	1.00 (0.45–2.25)	1.00
Cholangitis during 180-day	1(28)	5(388)/8(425)	0.68 (0.23–2.08)	0.50
Renal Failure	1(27)	1(48)/1(48)	-	1.00
Anaphylaxis	1(27)	0(48)/0(48)	-	1.00
Readmission	1(27)	1(48)/2(48)	-	-

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436


437

438

439

440

441



442

443 **Figure 1** The PRISMA flow diagram of selected studies.

444

445

446

447

448

449

450

451

452

453

454

455

456


457

458

459

460

461



462

463 **Figure 2** Risk of bias summary.

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489


490

491

492

493

494



495

496 **Figure 3** Forest plot of incidence of PEP between rectal NSAIDs alone and aggressive hydration
 497 combined with rectal NSAIDs.

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528


529

530

531

532

533



534

535 **Figure 4** Forest plot of incidence of severe PEP between rectal NSAIDs alone and aggressive hydration
536 combined with rectal NSAIDs.

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567


568

569

570

571

572



573

574 **Figure 5** Forest plot of incidence of fatal PEP between rectal NSAIDs alone and aggressive hydration
575 combined with rectal NSAIDs.